Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial

CONCLUSIONS: The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ early-stage breast cancer patients.PMID:38345755 | DOI:10.1158/1078-0432.CCR-23-2436

Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: John M S Bartlett Keying Xu Jenna Wong Gregory Pond Yi Zhang Melanie Spears Ranelle Salunga Elizabeth Mallon Karen J Taylor Annette Hasenburg Christos Markopoulos Luc Dirix Cornelis J H van de Velde Daniel Rea Catherine A Schnabel Kai Treuner Jane Bayani Source Type: research